Videos

Panelists discuss how subcutaneous checkpoint inhibitors are appropriate for most patients except those with severe emaciation limiting injection sites, with conversations emphasizing equivalent efficacy and safety data, quality-of-life benefits including shorter administration times, and addressing patient concerns about switching from intravenous (IV) treatment by highlighting convenience advantages while respecting patient preferences to remain on IV treatment if desired.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

Panelists discuss how subcutaneous formulations provide operational benefits through increased patient satisfaction, reduced chair time allowing higher patient throughput, cost savings from eliminated intravenous (IV) supplies and reduced infusion duration, improved nursing satisfaction from avoiding difficult venous access procedures, and potential for dedicated injection clinics or bays that free up traditional infusion center capacity.

Panelists discuss how operationalizing subcutaneous checkpoint inhibitors requires navigating temporary J-codes and reimbursement delays, maintaining physician-driven prescribing rather than automatic substitutions, considering future dynamics around 2028 biosimilar availability and Inflation Reduction Act impacts, and balancing patient convenience against potential economic implications from shifting away from intravenous (IV) formulations.

Panelists discuss how the phase 3 MK-3475-877 trial findings demonstrated subcutaneous pembrolizumab’s pharmacokinetic comparability to intravenous (IV) formulation with similar efficacy (45% vs 42% objective response rate [ORR]) and safety profiles in treatment-naive patients with metastatic non–small cell lung cancer, with indication-specific dosing of 395 mg every 3 weeks or 790 mg every 6 weeks combined with vorhyaluronidase.

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting operational challenges, including creating multiple electronic medical record (EMR) order sets, standardizing injection times and volumes across products, and addressing nursing workflow considerations during the 2- to 10-minute injection periods.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how pharmacokinetic equivalency across varied patient weights supports flat dosing, how immune-mediated adverse events remain unpredictable and not dose dependent, and how patients appreciate the mild, transient injection site reactions.

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

Jeneth Aquino, DNP, FNP-BC, explains that using ctDNA to guide a patient’s next steps can provide clarity in the treatment process.

Panelists discuss how subcutaneous checkpoint inhibitors offer benefits through reduced wait times, potential for injection rooms or examination room administration, streamlined pharmacy workflows, improved patient quality of life by making them feel less like “cancer patients,” and opportunities for home-based care delivery in underserved areas.

Panelists discuss how intravenous (IV) administration of immune checkpoint inhibitors creates challenges, including infusion chair bottlenecks, lengthy multistep clinic visits, difficult venous access over time, and significant time burdens for both patients and health care systems.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

Melissa Rikal, FNP-BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

Scott C. Borinstein, MD, PhD, discusses how holistic and empathetic care defines pediatric oncology.

Courtney Moore, APRN, FNP-C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.

Panelists discuss how practice improvements and patient resources can be implemented to empower both healthcare providers and ALK+ patients.

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Benjamin Besse, MD, PhD, shares AE management strategies for amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Panelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.

Panelists discuss how practice improvements and patient resources can be implemented to empower both health care providers and patients who have ALK-positive disease.

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.